HSBC: Two reasons why I think the bank has surged recently

Motley Fool contributor Jay Yao writes why he thinks HSBC has surged recently and why he is looking at the share as an attractive long-term investment option.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Covid-19 has hurt HSBC (LSE: HSBA) a lot. Because of the pandemic, the bank has had to take billions in additional loan loss provisions. Regulators pressured the bank to suspend its dividend at a time when many investors needed payments the most. HSBC has also had to postpone some of its restructuring efforts. 

As a result, HSBC stock has fallen substantially. Year-to-date, shares of the bank are down 37% at the time of this writing. 

Lately, however, the bank’s stock has rebounded from its lows. Shares are up around 30% from their lows in late September. 

Although the bank has rallied for a number of reasons, I believe a few factors are especially important. Here are two factors why I think HSBC has rallied since late September.

Vaccine expectations 

Although Covid-19 cases have surged in many parts of the West recently, I think HSBC stock has done well since September because the market is generally optimistic. It looks ahead and expects a brighter future. I think the market is reacting to progressively more positive expectations for a potential Covid-19 vaccine. 

Earlier in the year, I reckon vaccine expectations were rather low. A vaccine for a major ailment has never been developed and approved within a year. As a result, few expected a potential initial vaccine to be very effective or to be developed very quickly. Without a vaccine, it seemed unlikely that the world economy could recover quickly. 

As the year progressed, however, news about vaccine candidates around the world became more optimistic.

Recently, Pfizer, in conjunction with BioNTech SE, released rather promising efficacy results for their potential vaccine candidate. The news has made many investors even more optimistic.  

Once a safe and effective vaccine is approved and distributed widely enough, I reckon the world economy could grow rather quickly. Given the massive amount of fiscal and monetary stimulus at work, I think there is potential for upside surprise. 

If the global economy grows faster than expected, HSBC’s earnings could also grow faster than expected too, in my view. 

Given HSBC’s low price-to-book ratio, I still think it remains an attractive long-term investment option. 

China’s economic growth

Another reason I think HSBC stock has rallied is that China’s economy is recovering rather rapidly. 

Greater China accounts for a big part of the bank’s business. In 2019, Hong Kong accounted for 90% of HSBC’s pretax profits. The bank itself hopes to expand further in mainland China given the huge market and rising incomes there. 

Because the latest economic data from China has shown that the country has returned more or less to normal, I think the market has become more bullish on HSBC’s ability to continue to make profits in the area. 

If China’s economy could recover rather quickly once the virus was contained there, I think the world economy could do the same once a vaccine is adequately distributed. If that happens, I reckon HSBC’s ex-Greater China operations could also see an improvement in financial results. 

Jay Yao has no position in any of the shares mentioned. The Motley Fool UK has recommended HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bearded man writing on notepad in front of computer
Investing Articles

Have a £20,000 lump sum? Here’s how to target a £8,667 yearly passive income

How to turn £20,000 into a £8,667 passive income? Our Foolish author explains one counterintuitive strategy to build such an…

Read more »

British coins and bank notes scattered on a surface
Dividend Shares

2 dividend stocks that yield double the current UK interest rate

Following the latest UK interest rate cut, Jon Smith points out a couple of options that offer generous income relative…

Read more »

Investing Articles

A 9% yield and now this! Check out the stunning Taylor Wimpey share price forecast for 2026

Harvey Jones has kept the faith in Taylor Wimpey shares despite a difficult run, bolstered by their incredible yield. Next…

Read more »

Investing Articles

How much do you need in an ISA to aim for a life-changing passive income of £30,000 a year?

Harvey Jones says ISA savers can transform their futures in 2026 by investing in FTSE 100 dividend stocks with huge…

Read more »

Investing Articles

My top 10 ISA and SIPP stocks in 2026

Find out why a FTSE 100 investment trust is now this writer's top holding across his Stocks and Shares ISA…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

£10,000 invested in Rolls-Royce shares 5 Christmases ago is now worth…

James Beard reflects on the post-pandemic Rolls-Royce share price rally and whether the group could become the UK’s most valuable…

Read more »

Investing Articles

Will Nvidia shares continue their epic run into 2026 and beyond?

Nvidia shares have an aura of invincibility as an AI boom continues to benefit the chipmaker. Can anything stop the…

Read more »

Investing Articles

Can Babcock’s and BAE Systems’ shares blast off again in 2026?

The defence sector has been going great guns in 2025, so Harvey Jones looks at whether BAE systems’ and Babcock’s…

Read more »